Menopause, hormone therapy and women's health: what a generation was never told
Urologist and sexual medicine specialist Rachel Rubin joins Peter Attia for a wide-ranging conversation on menopause, hormone therapy and women's sexual health. They walk through the physiology of perimenopause, revisit how the Women's Health Initiative was interpreted, and map the practical toolbox of estradiol, progesterone and testosterone. A recurring theme: an entire generation of clinicians was never taught this material.
Overview
Rachel Rubin explains why urology — the specialty of quality of life — brought her to menopause medicine, and offers a memorable image for what happens hormonally at midlife: the gas tank. In the reproductive years the tank moves between a quarter and three-quarters full; in perimenopause it overflows and empties without warning; after menopause it simply sits empty. From there the conversation turns to the numbers behind the menstrual cycle, the role of FSH and LH, and why progesterone affects women so differently from one another.
Attia and Rubin then revisit the Women's Health Initiative, the trial whose press conference reshaped an industry overnight, and unpack the difference between the relative and absolute risk figures that drove the fear. They discuss the downstream cost: fewer than 6% of internal medicine, OB/GYN and family practice trainees receive even an hour of menopause education, and today under 4% of women use hormone therapy. Testosterone gets its own extended segment — an age-related decline starting in the thirties, with global consensus on its role in low libido yet no approved female formulation outside Australia.
Rubin then lays out the practical menu: micronized progesterone orally or vaginally, progestin-coated IUDs, and estradiol via patch, gel, ring, tablet or injection, each with tradeoffs worth matching to the person. The final third is devoted to what she calls her favourite topic — the genitourinary syndrome of menopause — and to the three most contentious questions in the field: timing, duration, and breast cancer history.
Key quotes
5Women at age 52, their gas tank is empty. Perimenopause is this time where it's very erratic — the tank is over full and then it goes to empty really quickly without warning.
They misinterpreted the data so drastically and scared everybody with so much fear that you actually have an entire generation that has forgotten how to prescribe hormone therapy.
The reality is this is half the population. This is not niche medicine.
I don't know who decided that men get testosterone and women have estrogen. We have both of the hormones.
If everybody in Medicare eligibility used vaginal estrogen, we would save Medicare between 6 and 22 billion dollars a year.
Key ideas
9Menopause is an abrupt event, not a slow slope
Male sex hormones decline gradually over decades, while a woman's ovarian output falls away over a short window around age 52. Rubin frames the difference as a slowly draining tank versus one that empties all at once.
Perimenopause is defined by inconsistency
Estradiol can read 200 on day one and 900 on day ten in the same person. The body keeps signalling for ovulation with a shrinking supply of eggs, sometimes overshooting dramatically, and it is the volatility itself that generates many symptoms.
Progesterone is experienced three different ways
Roughly a third of women find micronized progesterone transformative — mainly for sleep and anxiety — a third barely notice it, and a third react badly. The likely explanation involves progesterone metabolites acting at GABA receptors in the brain, but there is no way to predict the responder in advance.
There is also a risk to doing nothing
Medicine talks constantly about the risks of a medication and rarely about the risks of declining it. Rubin lists what accumulates in the hormone-free decades: bone loss, urinary tract infections, cardiovascular and cognitive concerns, and a mental-health picture that rarely returns to baseline.
Relative risk is not absolute risk
The Women's Health Initiative headline of a 24% increase in breast cancer incidence translated to an absolute increase of about 0.1% — roughly one additional case per thousand women, with no increase in breast cancer mortality. Attia notes that a large relative jump on a very small baseline changes little in practice.
The arm nobody reported
Women in the estrogen-only group — those without a uterus, who needed no progestin — showed a lower risk of both developing and dying from breast cancer. That finding never made the press conference, yet the warning label went onto every estrogen product.
A training gap, not just an information gap
Fewer than 6% of internal medicine, OB/GYN and family practice physicians receive even an hour of menopause education. The clinicians who knew how to prescribe retired or died without passing the skill on, so correcting the record is not enough on its own.
Testosterone declines from the thirties
Unlike estrogen, testosterone falls with age rather than with menopause, and receptors sit throughout the brain, bladder and genital tissue. There is global consensus that it helps low libido in postmenopausal women, yet no approved female product exists outside Australia.
Menopause is a whole-body event
Hormone receptors are everywhere, so the symptom list runs far past hot flashes: joint pain and frozen shoulder, sleep disruption, mood changes, brain fog, urinary urgency and recurrent infections. Rubin describes hormones as the body's lubrication system — for eyes, joints and tissue alike.
Practical takeaways
7- 1
Ask when in the cycle you feel worst 24:00
Mapping symptoms against the rise and fall of estrogen and progesterone turns a vague complaint into a pattern. Rubin literally draws the cycle with patients and asks them to mark where their bad days land.
- 2
Start one thing at a time 1:32:00
Both clinicians prefer to introduce estradiol first, then progesterone, then testosterone, so that any effect can be attributed to a specific change. Starting everything at once makes the picture impossible to read.
- 3
Give testosterone months, not weeks 1:36:30
Rubin tells patients to expect three to five months before the shift becomes obvious. Judging it after a few weeks usually means abandoning something that had not yet had a chance to work.
- 4
There should always be a menu 1:48:00
Patches, gels, sprays, rings, tablets and injections all behave differently across skin types, climates, saunas and routines. A practitioner who offers exactly one option is a warning sign.
- 5
Ask which assay is being used 1:54:00
Estradiol and testosterone measured on ELISA-based tests can be distorted by common supplements such as biotin. The more sensitive liquid chromatography assay costs a little more and is worth requesting by name.
- 6
Local and systemic are not the same thing 2:14:00
Whole-body hormone therapy often fails to resolve genital and urinary symptoms, and low-dose local preparations can be added without changing systemic levels. The two questions deserve to be asked separately.
- 7
Watch for the commercial red flags 2:22:00
A clinic selling its own compounded formulations, expensive saliva panels, or a single high-cost implant repeated four times a year deserves scepticism. Regulated products are widely available, inexpensive and usually covered by insurance.
Topics & chapters
15Why a urologist ended up here
Rubin describes urology as the quality-of-life specialty, board certified to care for everyone's genital and urinary tract, and how that led her toward women's sexual medicine.
The gas tank analogy
A picture of what separates the male hormonal decline from the abrupt event women experience around 52.
The numbers behind the cycle
Estradiol at 50, 150 and 3,000; the LH surge, ovulation, and where progesterone actually comes from.
Why progesterone hits everyone differently
GABA receptors, metabolites, and the three distinct patient responses seen in clinic.
Life without hormones
What accumulates in the decade after menopause when nothing is replaced — bone, bladder, brain and heart.
From the first prescriptions to the Women's Health Initiative
The 1960s, the endometrial cancer problem and its solution, then the trial that was halted early and the press conference that changed prescribing overnight.
24% versus 0.1%
Attia works through relative and absolute risk, and why the headline number was so misleading.
The generation that was never trained
Conferences without a single menopause course, specialists who say it isn't their field, and the resulting brain drain.
Testosterone in women
The age-related decline, receptors beyond libido, side effect realities, and the approval story that stalled.
Progesterone in practice
Micronized progesterone oral and vaginal, daily versus cyclic dosing, IUDs, and alternatives for those who react badly.
The estradiol menu
Tablets, patches, gels, sprays, rings and injections — absorption, adherence, cost and the two very different vaginal rings.
Labs, symptoms and Mount Stupid
Why the assay matters, where numbers genuinely help, and a shared scepticism about confident voices with little experience.
The whole-body symptom list
Joint pain, sleep, mood, brain fog and the research showing estrogen receptor density rising in the ageing brain.
Genitourinary syndrome of menopause
How the name changed, why the urinary half matters most, and the case Rubin makes for low-dose local therapy.
Timing, duration and finding good care
The timing hypothesis, why stopping at ten years has no basis, breast cancer history, and how to spot exploitative practices.